CERS - Cerus Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Concord,
United States
Type: Equity
CERS price evolution
CERS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.11 | $22.23 | $13.36 | |
| Short term investments | $58.79 | $51.65 | $54.2 | |
| Net receivables | $24.36 | $23.74 | $22.54 | $35.5 |
| Inventory | $36.54 | $53.09 | $57.77 | $59.37 |
| Total current assets | $140.61 | $135.03 | $138.17 | $144.44 |
| Long term investments | ||||
| Property, plant & equipment | $16.37 | $17.36 | $18.32 | $19.35 |
| Goodwill & intangible assets | $1.32 | $1.32 | $1.32 | |
| Total noncurrent assets | $50.47 | $50.97 | $53.31 | |
| Total investments | $58.79 | $51.65 | $54.2 | |
| Total assets | $189.54 | $185.5 | $189.14 | $197.75 |
| Current liabilities | ||||
| Accounts payable | $15.86 | $16.74 | $16.62 | $23.84 |
| Deferred revenue | $1.1 | $2.17 | $2 | |
| Short long term debt | $21 | $22.31 | $22.45 | |
| Total current liabilities | $54.34 | $53.88 | $57.24 | $67.52 |
| Long term debt | $64.85 | $77.69 | $78.3 | $73.55 |
| Total noncurrent liabilities | $81.31 | $81.73 | $76.78 | |
| Total debt | $98.69 | $100.6 | $96 | |
| Total liabilities | $136.05 | $135.19 | $138.97 | $144.3 |
| Shareholders' equity | ||||
| Retained earnings | -$1063.01 | -$1060.07 | -$1054.3 | -$1044.61 |
| Other shareholder equity | -$0.1 | -$0.87 | -$1.12 | -$1.27 |
| Total shareholder equity | $49.51 | $49.37 | $52.65 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $13.36 | $37.36 | $51.04 | $38.9 |
| Short term investments | $54.2 | $66.57 | $80.6 | $97 |
| Net receivables | $35.5 | $34.43 | $25.13 | $21.17 |
| Inventory | $59.37 | $29 | $26.79 | $23.25 |
| Total current assets | $144.44 | $170.14 | $187.1 | $183.43 |
| Long term investments | ||||
| Property, plant & equipment | $19.35 | $23.48 | $25.18 | $26.99 |
| Goodwill & intangible assets | $1.32 | $1.32 | $1.32 | $1.32 |
| Total noncurrent assets | $53.31 | $47.95 | $50.4 | $37.98 |
| Total investments | $54.2 | $66.57 | $80.6 | $97 |
| Total assets | $197.75 | $218.09 | $237.5 | $221.41 |
| Current liabilities | ||||
| Accounts payable | $23.84 | $33 | $35.61 | $24.21 |
| Deferred revenue | $2 | $0.59 | $0.67 | $0.58 |
| Short long term debt | $22.45 | $58.26 | $16.6 | $10.43 |
| Total current liabilities | $67.52 | $117.06 | $78.56 | $59.97 |
| Long term debt | $73.55 | $13.64 | $70.98 | $56.46 |
| Total noncurrent liabilities | $76.78 | $32.47 | $73.33 | $57.63 |
| Total debt | $96 | $87.24 | $87.59 | $66.89 |
| Total liabilities | $144.3 | $150.48 | $151.88 | $117.61 |
| Shareholders' equity | ||||
| Retained earnings | -$1044.61 | -$1007.12 | -$964.34 | -$909.97 |
| Other shareholder equity | -$1.27 | -$2.79 | -$0.15 | $0.67 |
| Total shareholder equity | $52.65 | $67.61 | $84.62 | $103.81 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $50.66 | $50.52 | $43.4 | $53.34 |
| Cost of revenue | $20.41 | $17.09 | $20.81 | |
| Gross Profit | $30.84 | $30.11 | $26.3 | $32.53 |
| Operating activities | ||||
| Research & development | $14.97 | $14.48 | $14.29 | |
| Selling, general & administrative | $18.97 | $19.8 | $17.27 | |
| Total operating expenses | $31.8 | $33.94 | $34.28 | $31.56 |
| Operating income | -$3.84 | -$7.98 | $0.98 | |
| Income from continuing operations | ||||
| EBIT | -$3.5 | -$7.38 | $0.97 | |
| Income tax expense | $0.08 | -$0.06 | $0.07 | $0.07 |
| Interest expense | -$2.5 | $2.33 | $2.23 | $2.23 |
| Net income | ||||
| Net income | -$2.93 | -$5.78 | -$9.69 | -$1.33 |
| Income (for common shares) | -$5.78 | -$9.69 | -$1.33 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $186.8 | $188.31 | $159.52 | $114.25 |
| Cost of revenue | $69.97 | $74.95 | $63.48 | $41.16 |
| Gross Profit | $116.83 | $113.36 | $96.04 | $73.09 |
| Operating activities | ||||
| Research & development | $67.64 | $64.11 | $63.69 | $64.41 |
| Selling, general & administrative | $75.52 | $83.33 | $81.29 | $67.02 |
| Total operating expenses | $146.88 | $147.44 | $144.98 | $131.43 |
| Operating income | -$30.05 | -$34.08 | -$48.94 | -$58.33 |
| Income from continuing operations | ||||
| EBIT | -$28.78 | -$36.46 | -$49.13 | -$55.83 |
| Income tax expense | $0.33 | $0.49 | $0.32 | $0.28 |
| Interest expense | $8.39 | $5.83 | $4.92 | $3.75 |
| Net income | ||||
| Net income | -$37.49 | -$42.78 | -$54.37 | -$59.86 |
| Income (for common shares) | -$37.49 | -$42.78 | -$54.37 | -$59.86 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$5.78 | -$9.69 | -$1.33 | |
| Operating activities | ||||
| Depreciation | $1.11 | $1.23 | $1.39 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.68 | $5.86 | $4.9 | |
| Total cash flows from operations | $0.4 | $1.96 | -$15.18 | |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$1.1 | $0.01 | |
| Investments | -$7.07 | $2.54 | $8.21 | |
| Total cash flows from investing | -$0.84 | -$7.11 | $1.45 | $8.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.44 | -$0.17 | ||
| Net borrowings | -$1.34 | $5.12 | $1.22 | |
| Total cash flows from financing | $4.22 | -$1.4 | $5.56 | $1.18 |
| Effect of exchange rate | $0.05 | -$0.02 | -$0.09 | -$0.02 |
| Change in cash and equivalents | $9.85 | -$8.13 | $8.88 | -$5.8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$37.49 | -$42.78 | -$54.37 | -$59.86 |
| Operating activities | ||||
| Depreciation | $4.91 | $4.56 | $4.57 | $4.46 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $20.27 | $24.46 | $23.57 | $18.03 |
| Total cash flows from operations | -$43.17 | -$25.61 | -$33.92 | -$40.74 |
| Investing activities | ||||
| Capital expenditures | -$4.6 | -$2 | -$0.91 | -$1.61 |
| Investments | $13.22 | $10.46 | $13.6 | -$47.94 |
| Total cash flows from investing | $8.62 | $8.46 | $12.69 | -$49.56 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.75 | $3.98 | $12.11 | $88.28 |
| Net borrowings | $9.92 | $0.21 | $21.18 | $3.5 |
| Total cash flows from financing | $10.67 | $4.19 | $34.29 | $91.78 |
| Effect of exchange rate | -$0.13 | -$0.73 | -$0.92 | |
| Change in cash and equivalents | -$24 | -$13.69 | $12.14 | $1.48 |
News
Fundamentals
| Market cap | $387.96M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 185.63M |
| Revenue | $197.91M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$19.73M |
| Revenue Q/Q | 7.21% |
| Revenue Y/Y | 7.11% |
| P/E ratio | -19.67 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.96 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.11 |
|---|---|
| ROA | -10.36% |
| ROE | N/A |
| Debt/Equity | 2.74 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.59 |
| Quick ratio | 1.92 |